Allogene Therapeutics (ALLO) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 6.5% versus a loss of 8.0%. Over five years, ZVRA leads with a -1.5% price change compared with -91.7% for ALLO. Zevra Therapeutics is the larger company by market cap ($590.3 million vs $452.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | ZVRA |
|---|---|---|
| Share price | $1.31 | $9.94 |
| Market cap | $452.59M | $590.27M |
| 1-day change | -2.24% | -3.21% |
| YTD return | -4.38% | +10.94% |
| 1-year return | +6.50% | -8.01% |
| 5-year return | -91.72% | -1.49% |
| P/E ratio (TTM) | — | 10.80 |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $-0.66 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $106.47M |
| Revenue growth (YoY) | -100.00% | +350.91% |
| Net income (latest FY) | $-190.89M | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | — | -59.12% |
| Net margin | — | 78.17% |
| 52-week high | $4.46 | $15.04 |
| 52-week low | $1.04 | $8.01 |
| Distance from 52-week high | -70.63% | -33.89% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +587.02% | +151.51% |
| Average volume | 5.66M | 1.07M |
| Shares outstanding | 345.49M | 59.38M |
| Employees | 150 | 61 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLO has outperformed ZVRA by 14.5 percentage points over the past year.
- Zevra Therapeutics grew revenue faster in its latest fiscal year (+350.91% vs -100.00%).
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Healthcare · Biotechnology · 150 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Healthcare · Biotechnology · 61 employees
ALLO vs ZVRA FAQ
Which is bigger, Allogene Therapeutics or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $590.27M compared with $452.59M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or ZVRA?
ALLO returned +6.50% over the past 12 months, compared with -8.01% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.